Search

Your search keyword '"Shalaev, Sergey"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Shalaev, Sergey" Remove constraint Author: "Shalaev, Sergey"
24 results on '"Shalaev, Sergey"'

Search Results

1. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

3. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

4. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

5. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

7. Wind Tunnel Testing of Adaptive Wing Structures

8. Contributors

9. AuNP Aptasensor for Hodgkin Lymphoma Monitoring

10. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

11. Poster: ABCL-256: The Interim Results of the Significance of Upfront High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IV Stage and High-Intermediate/High Risk Groups of Diffuse Large B-Cell Lymphoma with Complete Response after Induction Chemotherapy

12. ABCL-256: The Interim Results of the Significance of Upfront High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IV Stage and High-Intermediate/High Risk Groups of Diffuse Large B-Cell Lymphoma with Complete Response after Induction Chemotherapy

13. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

14. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

15. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

16. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

17. Chapter 23 - Wind Tunnel Testing of Adaptive Wing Structures

18. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

20. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

22. Broken Chain of Treatment as an Independent Prognostic Factor Affecting Survival after Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

23. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

24. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Catalog

Books, media, physical & digital resources